PGP and peripheral neuropathy: Our simulations indicate that vincristine muscle concentrations increase following ibrutinib administration when a low P-gp IC50 is used, which is consistent with the observation of an increased incidence of peripheral neuropathy, potentially due to vincristine, in patients receiving ibrutinib and R-CHOP combination therapy [5].